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	 The	 photostability	 of	 gemifloxacin	mesylate	 (GFLX)	 and	 lomefloxacin	 hydrochloride	 (LFLX)
antibacterial	agents	in	dilute	aqueous	solutions	(bulk	powder	and	dosage	form)	was	studied
by	applying	the	International	Conference	on	Harmonization	(ICH)	recommended	conditions.
The	 photodegradation	 processes	 were	 monitored	 by	 UV‐Vis	 spectrophotometry	 and
quantified	by	HPLC.	The	structures	of	degradation	products	in	the	aqueous	solution	have	been
deduced	 from	 LC‐MS/MS.	 The	 GFLX	 and	 LFLX	 photodegradation	 kinetic	 rates	 were	 also
determined.	The	photodegradation	process	for	GFLX	and	LFLX	solutions	can	be	described	as
first	 order	 kinetic	with	 rate	 constants	 0.105	 and	 0.119	1/h,	 respectively,	 under	 the	 applied
experimental	conditions.	The	photodegradation	rates	of	GFLX	(0.119	1/h)	and	LFLX	(0.0.157
1/h)	 in	aqueous	solutions	were	higher	 in	dosage	 forms	 than	bulk	powder.	Titanium	dioxide
cannot	 be	 used	 as	 an	 opacifier	 with	 these	 fluoroquinolone	 drugs	 because	 the	 rates	 of
photodegradation	of	GFLX	(0.0.161	1/h)	and	LFLX	(0.0.164	1/h)	were	significantly	enhanced
by	 the	 addition	 of	 TiO2.	 The	 obtained	 results	 showed	 that	 these	 fluoroquinolone	 drugs	 are
photolabile,	 thus	 these	 two	 drugs	 should	 be	 strictly	 protected	 from	 light	 during	 storage,
administration	and	drug	analysis.	
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1.	Introduction	
	
Drug	 photostability	 constitutes	 an	 important	 current	
subject	 of	 investigation	 as	 the	 photodegradation	 process	 can	
result	 in	 a	 loss	 of	 the	 potency	 of	 drug	 and	 also	 may	 cause	
adverse	 effects	 due	 to	 the	 formation	 of	 toxic	 degradation	
products	[1‐5].	
As	a	consequence,	various	pharmacopoeias	prescribe	 light	
protection	for	a	number	of	drugs	and	adjuvants	during	storage.	
Knowledge	of	the	photochemical	and	photophysical	properties	
of	 drugs	 is	 essential	 to	 ensure	 adequate	 product	 quality	 and	
also	 for	 predicting	 drug	 phototoxicity.	 To	 this	 end,	 specific	
guidelines	 for	 the	 phototoxicity	 testing	 on	 drugs	 have	 been	
proposed	 by	 the	 International	 Conference	 on	 Harmonization	
(ICH)	 [1].	 Some	 classes	 of	 drugs	 have	 been	 investigated	
thoroughly	 for	 their	 photostability	 and	 phototoxicity	 [1,6‐8].	
Studies	 of	most	 fluoroquinolones	 (FQs)	developed	 in	 the	 past	
have	 reported	 that	 they	 cause	 phototoxicity	 with	 various	
degrees	of	severity	[9].	
Derivatives	of	this	class	of	drugs	containing	a	halogen	atom	
at	 position	 8	 were	 found	 to	 have	 the	 greatest	 phototoxic	
properties.	 Lomefloxacin,	 sparfloxacin,	 fleroxacin,	 and	
clinafloxacin	 are	 included	 in	 this	 group	 of	 FQs.	 On	 the	 other	
hand,	 a	 hydrogen	 group	 at	position	8	provides	 a	 FQ	molecule	
with	only	a	mildly	phototoxic	potential	[9‐12].	UV	irradiation	of	
8‐halogenoquinolones	 has	 been	 reported	 to	 cause	 photo‐
instability	 [13‐16].	 FQ	 derivatives	 with	 a	 methoxy	 group	 at	
position	 8,	 such	 as	 gatifloxacin	 and	 moxifloxacin,	 have	 been	
demonstrated	 to	 be	 the	 most	 photostable	 and	 the	 least	
phototoxic	 [1].	 Knowledge	 about	 the	 photostability	 of	 drug	
substances	and	drug	products	is	thus	also	important	to	provide	
information	 in	 the	 handling,	 packaging	 and	 labelling	 of	 drug	
products	[1,17].	
Gemifloxacin	 mesylate	 (7‐[(4Z)‐3‐(aminomethyl)‐4‐
methoxyimino‐pyrrolidin‐1‐yl]‐1‐cyclopropyl‐6‐fluoro‐4‐oxo‐
1,8‐aphthyridine‐3‐carboxylic	 acid	 [18]	 (Figure	 1)	 and	
lomefloxacin	 (RS)‐1‐ethyl‐6,8‐difluoro‐7‐(3‐methyl	 piperazin‐
1‐yl)‐4‐oxo‐quinoline‐3‐carboxylic	 acid	 [18]	 (Figure	 2)	 are	
antibacterial	 agents.	 They	 have	 a	 broad	 antibacterial	
spectrum.Consequently,	 they	 are	 clinically	 used	 as	 the	
antibiotics	 of	 first	 choice	 for	 general	 bacterial	 infectious	
diseases	and	their	efficacies	are	highly	appreciated	[19].		
	
 
	
Figure	1.	 Chemical	 structures	of	 gemifloxacin,	 7‐[(4Z)‐3‐(aminomethyl)‐	 4‐
methoxyimino‐pyrrolidin‐1‐yl]‐1‐cyclopropyl‐6‐fluoro‐4‐oxo‐1,8‐
naphthyridine‐3‐carboxylic	acid.	
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Figure	2.	Chemical	 structures	 of	 lomefloxacin,	 (RS)‐1‐Ethyl‐6,8‐difluoro‐ 7‐
(3‐methylpiperazin‐1‐yl)‐	4‐oxo‐quinoline‐3‐carboxylic	acid.	
	
	
The	present	study	deals	with	the	photostability	of	GFLX	and	
LFLX	under	a	combination	of	a	near	UV	fluorescent	lamp	and	a	
cool	white	 fluorescent	 lamp	(option	2).	 In	addition,	 this	study	
clarifies	the	effect	of	TiO2	addition	on	the	photostability	of	these	
drugs	 in	 their	 aqueous	 solutions.	 The	photo	decomposition	of	
these	drugs	was	monitored	by	UV	spectrophotometric	method,	
HPLC	and	LC‐MS/MS.	
	
2.	Experimental	
	
2.1.	Chemicals	and	reagents	
	
GFLX	(99.9%)	and	Factive	 tablets	were	kindly	supplied	by	
Hikma	 Pharma	 S.A.E.	 (Egypt).	 LFLX	 (99.8%)	 and	 Maxa‐
Floxtablets	were	kindly	supplied	by	Pharaoina	Co.,	(Egypt).	LC‐
MS	grade	acetonitrile	and	formic	acid	were	purchased	from	(E‐
Merck,	 Darmstadt,	 Germany).	 Citric	 acid	 and	 sodium	 citrate	
were	purchased	from	(Finechem,	Egypt).	Titanium	dioxide	was	
purchased	 from	 Qualikems	 (New	 Delhi,	 India).	 Water	 was	
obtained	from	a	Milli‐Q	water	purification	system	(Millipore	Co,	
France).	 The	mobile	 phase	 component	was	 filtered	 through	 a	
0.45	µm	Whatman	membrane	filter	prior	to	its	use.	
	
2.2.	Instruments	and	chromatographic	conditions	
	
CLIMACELL	chamber	(MMM	group,	Germany)	was	used	as	
a	 photostability	 testing	 device).	 It	 is	 equipped	 with	 a	
microprocessor‐controlled	 system	 of	 humidification	 and	
dehumidification	 with	 a	 powerful	 lighting	 system	 that	
guarantees	excellent	homogenous	parameters	for	testing	(near	
UV	 light	 fluorescent	 lamp	 and	 cool	 white	 fluorescent	 lamp).	
Working	 temperature	 used	 ranged	 from	 0.0	 up	 to	 99.9	 °C	
(without	 humidity)	 and	 from	 10	 to	 90.0	 °C	 (with	 humidity).	
Inner	glass	door	and	 inner	chamber	 is	made	of	 stainless	steel	
DIN	1.4301	 (AISI	304).	 It	 contains	 a	 shelf	 for	putting	 samples	
and	a	sensor	for	irradiance	measurements.		
Absorption	 spectra	 were	 measured	 on	 Shimadzu	 UV‐VIS	
spectrophotometer	 from	Helios	Company.	 It	 is	 a	 double	beam	
spectrophotometer	 with	 two	 matched	 1	 cm	 quartz	 cells,	
connected	to	an	IBM	compatible	personal	computer	(PC)	and	a	
HP‐600	inkjet	printer.		
Analysis	 for	 drug	 solutions	 before	 and	 after	 illumination	
was	 performed	 on	 high	 performance	 liquid	 chromatographic	
system	(Waters,	Milford,	USA)	equipped	with	pump	controlled	
by	Waters	 610	 controller,	 Waters	 717	 auto	 sampler	 injector,	
Waters	 486	 variable	 wavelength	 UV	 detector.	 For	 the	 data	
acquisition	 and	 integration	 Waters	 Empower	 software	
operated	by	Pentium	III	(450MHz)	processor	(Lenovo,	UK)	was	
used.	The	analytical	column	employed	was	Thermo	C18	column	
(150	×	4.6	mm,	id).The	mobile	phase	consisted	of	a	mixture	of	
citrate	 buffer	 (pH	 =	 2.5)	 and	 acetonitrile	 (70:30,	 v:v)	 The	
mobile	phase	was	freshly	prepared	and	was	filtered	before	use.	
All	 separations	were	 performed	 isocratically	 at	 a	 flow	 rate	 of	
1.5	mL/min	and	column	condition	was	maintained	at	ambient	
temperature.	Peaks	were	monitored	by	UV	detector	adjusted	at	
270	nm.	
Separation	 and	 detection	 for	 photodegradation	 products	
were	 performed	 on	 Agilent	 Triple	 quadrupoles	 mass	
spectrometer	 with	 API	 source	 coupled	 with	 Agilent	 pump	
controlled	 by	 Agilent	 1200	 controller	 and	 equipped	 with	
Agilent	 1200	 auto	 sampler	 injector.	 For	 the	 data	 acquisition	
and	 integration,	 Agilent	 MassHunter	 software	 operated	 by	
Pentium	 III	 (450	 MHz)	 processor	 (HP,	 USA).	 Agilent	 SB‐C18	
(50×4.6	 mm),	 1.8	 µm	 particle	 size	 column	 was	 used	 for	
separation	of	photodegradation	peaks	using	acetonitrile:	0.1%	
formic	acid	(84:16,	v:v)	as	mobile	phase	with	flow	rate	was	0.6	
mL/min.	
	
2.3.	Sample	preparation	and	irradiation	
	
The	 tested	 GFLX	 and	 LFLX	 samples	 were	 prepared	 as	
follows:	Stock	solutions	of	concentration	1×10‐3	M	of	GFLX	and	
LFLX	 were	 prepared	 in	 double	 distilled	 water.	 Working	
standard	 solutions	 of	 1×10‐5	 M	 of	 GFLX	 and	 LFLX	 were	
prepared	by	appropriate	dilution	from	the	corresponding	stock	
solution	in	double	distilled	water.	The	drug	solution	was	placed	
into	 quartz	 cuvette	 with	 stopper	 and	 measured	 using	
spectrophotometry	 as	 a	 reference	 (zero	 time)	 then	 placed	 in	
the	 chamber	 for	 different	 periods	 of	 time	 followed	 by	
spectroscopic	 analysis	 and	 compared	with	 control	 samples	 of	
the	 drug	which	 covered	with	 an	 aluminium	 foil	 placed	 in	 the	
chamber	for	the	same	periods	of	time.	
GFLX	and	LFLX	market	tablets	were	extracted,	purified	and	
prepared	in	double	distilled	water	in	the	same	concentration	as	
their	corresponding	drugs.	Their	spectra	were	measured	before	
and	 after	 illumination.	 The	 effect	 of	 titanium	 dioxide	 on	 the	
photostability	 of	 drug	 solutions	 was	 investigated	 using	 a	
solution	 consisting	 of	 a	 typical	 combination	 of	 drug	 solutions	
and	TiO2;	loading	100	mg/L.	The	experiments	were	carried	out	
with	100	mL	of	drug	solutions.	The	drug	solutions	were	stirred	
in	dark	for	30	min	after	the	addition	of	titanium	dioxide.	5	mL	
of	samples	of	suspension	were	withdrawn	at	different	intervals,	
immediately	were	centrifuged	at	3000	rpm	for	10	min	and	the	
supernatant	 was	 filtered	 through	 syringe	 filter	 0.45	 μm	 pore	
size.	Changes	in	absorbance	were	monitored	spectroscopically.	
	
3.	Results	and	discussions	
	
A	 literature	 survey	 reveals	 no	 photostability	 studies	 for	
GFLX	 and	 LFLX	 were	 determined	 according	 ICH	 guidelines,	
thus	 the	 goal	 of	 this	 work	was	 to	 study	 the	 photostability	 of	
these	 drugs	 in	 their	 bulk	 powders	 and	 dosage	 forms.	 In	
addition,	 this	work	 clarifies	 the	 effect	 of	 TiO2	 addition	 on	 the	
photostability	of	these	drugs	in	their	aqueous	solutions.	
Photostability	 of	 GFLX	 and	 LFLX	 in	 bulk	 powder	 was	
examined	 in	 aqueous	medium.	 Samples	 were	 irradiated	 with	
two	light	doses	for	eight	hours,	Dose	(I)	69	w.m‐2.h‐1	for	UV	and	
Dose	(II)	75.3	kilolux	for	visible.	The	effect	of	radiation	on	drug	
solutions	was	monitored	by	recording	their	absorption	spectra	
at	different	time	intervals.	
The	maximum	absorption	of	GFLX	and	LFLX	was	observed	
at	two	wavelengths,	340	and	268	nm	for	GFLX	and	at	327	and	
278	nm	 for	 LFLX.	When	 aqueous	 solutions	 of	GFLX	 and	LFLX	
were	 irradiated,	 spectral	 changes	 were	 observed	 in	 their	
solutions.	For	GFLX	the	wavelength	was	shifted	to	331	and	264	
nm	 after	 irradiation,	 besides	 a	 remarkable	 decrease	 in	 its	
maximum	absorption	with	 increasing	 irradiation	 time	 (Figure	
3).	The	maximal	absorptions	of	LFLX	at	327	and	278	nm	were	
shifted	to	324	and	273	nm.	Similarly,	the	absorption	spectrum	
of	 LFLX	 was	 remarkably	 decreased	 by	 increasing	 irradiation	
time	 (Figure	 4).	 The	 UV	 spectra	 recorded	 of	 these	 two	 drugs	
show	 a	 hypsochromic	 shift	 ranged	 from	 2	 to	 9	 nm	 which	
indicates	the	loss	of	a	weak	chromphoric	group	such	as	fluorine	
atom,	thus	photodeflouration	occurred	[20].	
Therefore,	the	aqueous	solutions	of	GFLX	and	LFLX	in	their	
bulk	powder	 are	photo‐chemically	 unstable	 and	 their	 rates	 of	
photodegradation	obey	first	order	of	kinetic	law.	By	plotting	ln	
A	(Absorbance)	versus	time	of	 illumination,	 the	rate	constants	
of	 photodegradation	 are	 0.105	 and	 0.119	 1/h	 for	 GFLX	 and	
LFLX,	 respectively	 (Figure	 3	 and	 4).	 The	 rate	 of	 photodegra‐
dation	 of	 LFLX	 is	 slightly	 greater	 than	 GFLX,	 this	means	 that	
LFLX	is	more	photolabile	than	GFLX.	This	may	be	attributed	to	
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the	fact	that	high	degree	of	flourations	may	result	in	decreasing	
photostability	 [21].	 Thus	 LFLX	 (6,8‐diflourinated	 quinolones)	
was	 found	 to	 be	 less	 stable	 than	 GFLX,	 6‐monoflourinated	
quinolones.	
	
	
	
Figure	 3.	 Change	 in	 absorption	 spectra	 of	 gemifloxacin	 solution	 after	
irradiation	and	determination	of	its	rate	of	photodegradation.	
	
	
	
	
Figure	 4.	 Change	 in	 absorption	 spectra	 of	 	 lomefloxacin	 solution	 after	
irradiation	and	determination	of	its	rate	of	photodegradation.	
	
3.1.	HPLC	analysis	
	
On	 the	 analysis	 of	 non‐irradiated	 and	 irradiated	 GFLX	
solutions	 by	 HPLC,	 the	 chromatogram	 corresponding	 to	 non‐
irradiated	 solution	 showed	 characteristic	 peak	 of	 the	 drug	 at	
retention	time	2.932	min	(Figure	5A),	and	the	chromatogram	of	
GFLX	solution	after	irradiation	exhibited	four	peaks	which	are	
corresponding	 to	 four	 degradation	 products	 with	 retention	
time	at	2.547,	2.887,	3.100	and	3.369	min,	respectively	(Figure	
5B).	
The	non‐irradiated	and	irradiated	LFLX	solutions	were	also	
analyzed	 by	 HPLC.	 The	 chromatogram	 of	 non‐irradiated	
solution	 showed	 only	 the	 peak	 of	 the	 drug	 at	 retention	 time	
2.310	min	(Figure	6A)	and	the	chromatogram	of	GFLX	solution	
after	 irradiation	exhibited	 three	peaks	corresponding	 to	 three	
degradation	 products	 with	 retention	 time	 2.752,	 3.161	 and	
3.442	min,	respectively	(Figure	6B).	
	
	
Figure	 5.	 HPLC	 chromatogram	 of	 gemifloxacin	 (A)	 pre‐exposure	 and	 (B)	
post‐exposure	to	the	illumination.	
	
	
	
	
 
 
Figure	 6.	HPLC	 chromatogram	 of	 	 lomefloxacin	 (A)	 pre‐exposure	 and	 (B)	
post‐exposure	to	the	illumination.	
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Scheme	1
	
	
3.2.	LC‐MS/MS	analysis	
	
The	 LC‐MS/MS	 was	 used	 to	 illustrate	 the	 degradation	
pathway	 for	 both	GFLX	 and	LFLX.	The	mass	 spectra	 for	GFLX	
solution	 before	 and	 after	 illumination	 were	 recorded.	 The	
molecular	ion	of	GFLX	before	illumination	was	detected	at	m/z	
390.5	 (M+	H)	 (Figure	7A).	 The	mass	 spectra	of	GFLX	 solution	
after	illumination	exhibited	a	complete	degradation	of	the	drug	
solution	 and	 formation	 of	 four	 degradation	 products	 with	
molecular	 masses	 as	 follows:	 335	 (M‐F,	 COOH),	 301(M‐F,	
COOH,	CH3O),	294	(M–C6N3OH11)	and	289	(M‐F,	COOH,	CH3ON)	
for	Degradation	1	(Deg.	1),	Degradation	2	(Deg.	2),	Degradation	
3	(Deg.	3)	and	Degradation	4	(Deg.	4),	respectively	(Figure	7B).	
The	representative	total	ion	chromatogram	of	GFLX	solution	in	
MRM	mode	 after	 illumination	was	 shown	 in	 (Figure	 8A)	 and	
the	 extracted	 ion	 chromatograms	 prove	 the	 presence	 of	 four	
degradation	 products	 (Figure	 8B‐E),	 respectively.	
Photodegradation	 pathways	 of	 GFLX	 were	 proposed	 and	
illustrated	in	Scheme	1.	
Mass	 spectra	 for	 LFLX	 solution	 before	 and	 after	
illumination	 were	 recorded.	 The	 molecular	 ion	 of	 LFLX	
spectrum	before	 illumination	(Figure	9A)	was	detected	at	m/z	
352.5	 (M+H).	 The	 mass	 spectra	 of	 LFLX	 solution	 after	
illumination	 (Figure	9B)	exhibited	a	 complete	degradation	 for	
the	drug	solution	and	formation	of	three	degradation	products	
which	 displayed	 at	 332	 (M‐F),	 290	 (M‐F,	 COOH)	 and	 251	 (M‐
C5N2H12)	for	Deg.	1,	Deg.	2,	and	Deg.	3,	respectively	(Figure	9B).	
The	representative	total	ion	chromatogram	of	LFLX	solution	in	
MRM	mode	after	 illumination	was	shown	 in	 (Figure	10A)	and	
the	 extracted	 ion	 chromatograms	prove	 the	presence	of	 three	
degradation	 products	 (Figure	 10B‐D),	 respectively.	 Different	
photodegradation	 pathways	 of	 LFLX	 were	 proposed	 and	
illustrated	in	Scheme	2.	
	
	
	
3.3.	Photostability	of	GFLX	and	LFLX	in	their	dosage	form	
	
The	photostability	of	GFLX	and	LFLX	 in	 their	dosage	 form	
was	 also	 studied.	 Remarkable	 decreases	 in	 absorbance	 were	
observed	as	illumination	time	increased	(Figure	11	and	12).		
	
	
	
	
Figure	 7.	MS/MS	 spectra	 of	 gemifloxacin	 (A)	 pre‐exposure	 and	 (B)	 post‐
exposure	to	the	illumination.	
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Table	1.	Rates	of	photodegradation	of	GFLX	and	LFLX	in	aqueous	solutions.	
Drug		 Rate	of	photodegradation	in	aqueous	
solution,	(Row	material)	(1/h)	
Rate	of	photodegradation	in	aqueous	
solution,	(Tablet	form)	(1/h)
Rate	of	photodegradation	in	aqueous	solution,	
(Row	material	in	presence	of	TiO2)	(1/h)
GFLX	 0.105	 0.119 0.161
LFLX	 0.119	 0.157 0.164
	
	
	
	
	
	
	
Figure	 8.	 A	 representative	 total	 ion	 chromatogram	 in	 MRM	 mode	 of	
irradiated	solution	of	gemifloxacin	(A)	and	the	extracted	ion	chromatogram	
of	photodegradation	products	(B,	C,	D,	and	E).	
	
	
	
Figure	 9.	MS/MS	 spectra	 of	 lomefloxacin	 (A)	 pre‐exposure	 and	 (B)	 post‐
exposure	to	the	illumination.	
	
GFLX	and	LFLX	in	their	dosage	forms	were	also	found	to	be	
photolabile	 and	 their	 kinetic	 rates	 of	 photodegradation	 were	
0.119	1/h	for	GFLX	and	0.157	1/h	for	LFLX,	respectively	(Table	
1).	
The	rate	of	photodegradation	of	these	drugs	in	their	dosage	
form	is	greater	than	in	their	bulk	powder.	There	is	a	decrease	in	
the	 stability	 of	 GFLX	 and	 LFLX	 in	 their	 dosage	 forms,	
interference	 of	 one	 or	 more	 of	 the	 excipients	 might	 be	
contributing	 to	 the	 increase	 of	 their	 degradation	 [22].	
Excipients	 can	 initiate,	 propagate	 or	 participate	 in	
photochemical	 reactions	 [23,24].	 So	 excipients	 used	 in	 these	
drugs	 preparation	 strongly	 influenced	 the	 photodegradation	
kinetics.	 The	 stability	 testing	 for	 the	 final	 pharmaceutical	
products	is	very	important.	
	
3.4.	Photostability	of	GFLX	and	LFLX	in	presence	of	TiO2	
	
The	 photostability	 of	 these	 drugs	 were	 investigated	 in	
aqueous	 solutions	 in	 the	 presence	 of	 titanium	 dioxide.	 The	
rates	of	photodegradation	of	GFLX	and	LFLX	were	significantly	
enhanced	by	the	addition	of	TiO2	(Table	1)	in	comparison	with	
rates	 of	 photodegradation	 of	 these	 drugs	 in	 direct	
photodegradation	 (without	 TiO2).	 Photodegradation	 process	
occurred	due	to	the	adsorbing	of	drugs	over	TiO2	particles	and	
the	photodegradation	is	driven	by	injecting	of	an	electron	from	
excited	state	of	drug	into	the	conduction	band	of	TiO2	particles	
which	 leads	 to	 the	 oxidation	 of	 drug	 molecules,	 also	 the	
electron	 of	 conduction	 band	 caused	 by	 moving	 the	 electrons	
from	 valence	 band	 and	 these	 electron	 may	 be	 used	 to	 drive	
another	photoreactions	of	drug	molecules	in	different	routes.		
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Figure	 10.	 A	 representative	 total	 ion	 chromatogram	 in	 MRM	 mode	 of	 irradiated	 solution	 of	 lomefloxacin	 (A)	 and	 the	 extracted	 ion	 chromatogram	 of	
photodegradation	products	(B,	C,	and	D).		
	
	
So	 the	 presence	 of	 TiO2	 causes	 photocatalytic	 activity,	 the	
mechanism	 of	 photocatalysis	 can	 be	 explained	 in	 details	 as	
follows	equations	(1‐7)	
	
TiO2	+	hѵ	→	e‐cb	+	h+ѵb 	 	 	 	 (1)	
	
H2Oads	+	h+ѵb	→	HO·ads	+	H+		 		 	 	 (2)	
	
O2	+	e‐cb	→	O·‐2		 	 		 	 	 (3)	
	
O·‐2	+	H+	→	HO·2		 	 	 	 	 (4)	
	
HO·2	+	HO·2	→	H2O2			 	 	 	 (5)	
	
H2O2	+	e‐cb	→	HO‐	+	HO·			 		 	 	 (6)	
	
D	+	h+ѵb	→	D+·						 	 		 	 	 (7)	
	
Equation‐1	 shows	 the	 initial	 reaction	 of	 titanium	 dioxide	
with	 light,	 producing	 a	 hole	 and	 an	 electron	 that	 act	 as	 the	
active	excited	species,	which	then	react	with	water	and	oxygen	
as	shown	in	equations	2‐5.	In	aqueous	conditions,	Ti‐OH	groups	
are	abundant	and	are	the	major	source	of	hydroxyl	radicals	on	
the	 TiO2	 surface	 [25]	 .The	 downstream	 products	 of	 reactions	
with	molecular	 oxygen	 are	 superoxide	 (O2·‐,	 Equation	 3)	 and	
often	hydroxyl	radical	(HO‐,	Equation	5),	which	can	react	with	a	
nearby	drug	molecule.	Equations	5	and	6	show	the	formation	of	
hydrogen	peroxide,	which	 is	known	to	split	 into	two	hydroxyl	
radicals	through	aqueous	photolysis	or	to	accept	an	electron	as	
in	Equation	6	[26].	
The	 hole	 (h+ѵb,)	 can	 also	 react	 directly	 with	 an	 adsorbed	
drug	 donor	 (D)	 as	 in	 Equation	 7.	 The	 presence	 of	 titanium	
dioxide	 enhanced	 the	 rates	 of	 photodegradation.	 So	 titanium	
dioxide	 cannot	 be	 used	 as	 photoprotective	 agent	 with	 these	
drugs.	
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Figure	 11.	 Change	 in	 absorption	 spectra	 in	 the	 solution	 of	 GFLX	 (drug	
product)	after	irradiation	and	determination	of	its	rate	of	photodegradation.	
	
4.	Conclusion		
	
The	 present	 study	 reveals	 the	 photolability	 of	 GFLX	 and	
LFLX	in	their	bulk	powder	and	their	dosage	forms.	The	rates	of	
photodegradation	 of	 these	 fluoroquinolone	 drugs	 in	 their	
dosage	 forms	 are	 greater	 than	 in	 their	 bulk	 powder,	 thus	
occurring	 of	 photodegradation	 may	 be	 attributed	 to	
participating	 of	 the	 excipients	 used	 in	 the	 photochemical	
reaction.	 Titanium	dioxide	 cannot	 be	 used	 as	 photoprotective	
agent	with	these	fluoroquinolone	drugs.	It	is	necessary	to	avoid	
exposure	of	these	drugs	to	light	effects	so	special	care	must	be	
taken	 during	 the	 preparation,	 manufacturing	 and	 storage	 of	
these	drugs.	Finally,	the	knowledge	of	drug‐light	interactions	is	
a	 necessary	 prerequisite	 to	 the	 development	 of	 dosage	 forms	
that	are	stable	and	of	good	quality.	
	
	
	
Figure	 12.	 Change	 in	 absorption	 spectra	 in	 the	 solution	 of	 LFLX	 (drug	
product)	after	irradiation	and	determination	of	its	rate	of	photodegradation.	
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